NIK-626; a dual inhibitor of thromboxane synthase and 5-lipoxygenase, potential candidate as a novel anti-asthma compound Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Dual inhibition of thromboxane synthase and 5-lipoxygenase, potentially significant mechanism for the treatment of asthma Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Pharmacological properties of a novel PI3Kd inhibitor, DS-1515 Source: International Congress 2018 – Basic pharmacology Year: 2018
Effect of thromboxane A2 (TXA2 ) synthase inhibitor and TXA2 receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001
Effects of selective and unselective endothelin-receptor antagonists on prostacyclin synthase gene expression in pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007
Direct relationship between inhibition of leukotriene release in lung and free plasma concentration of a LTC4 synthase inhibitor in a rat model Source: International Congress 2015 – New models for treating airway diseases Year: 2015
Effects of endothelial nitric oxide synthase enzyme, angiotensin converting enzyme and serotonin transporter genotypes on pulmonary hypertension in COPD Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010
Effects of selective and non-selective cyclooxygenase inhibition on exhaled eicosanoids in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 578s Year: 2004
Correction of endothelial dysfunction by inhibitors of phosphodiesterase-5 in combination with L-arginine Source: Annual Congress 2013 –Pulmonary circulation: animal models and experimental treatments Year: 2013
Pharmacological characterization of CHI25243, a novel potent inhaled inhibitor of neutrophil elastase Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016
Differential actions of phosphatidyinositol 3-kinase inhibitors on respiratory burst and leukotriene C4 generation in PAF-stimulated human eosinophils Source: Eur Respir J 2003; 22: Suppl. 45, 547s Year: 2003
The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilastSource: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
No direct inhibition of NO synthases by montelukast Source: Eur Respir J 2004; 24: Suppl. 48, 578s Year: 2004
Inhibition of the glycogen synthase kinase 3β reduces steroid function in human monocytes Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Effects of inducible nitric oxide synthase and xanthine oxidase inhibitors on SEB-induced interstitial pneumonia in mice Source: Eur Respir J 2002; 19: 447-457 Year: 2002
The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001